Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Hyperbilirubinemia in the premature infant (less than 35 weeks gestation)

INTRODUCTION

Almost all preterm infants less than 35 weeks gestational age (GA) have elevated total serum/plasma bilirubin (TB) levels, which results in neonatal jaundice, the yellowish discoloration of the skin, and/or conjunctiva caused by bilirubin deposition. The major complication of an elevated TB (hyperbilirubinemia) is bilirubin-induced neurologic dysfunction (BIND), which occurs when circulating bilirubin crosses the blood-brain barrier and binds to brain tissue. Acute bilirubin encephalopathy (ABE) is the acute and reversible form of BIND, while kernicterus is the chronic and permanent neurologic sequelae of BIND.

Therapeutic interventions (ie, phototherapy and exchange transfusion) reduce the TB levels in the blood, which is thought to prevent BIND and, hence, kernicterus. In infants at or greater than 35 weeks GA (ie, term and late preterm infants), universally-accepted guidelines based upon an age-specific, percentile-based TB nomogram are used to decide when to initiate phototherapy and exchange transfusions to prevent severe hyperbilirubinemia and BIND [1]. (See "Treatment of unconjugated hyperbilirubinemia in term and late preterm infants".)

However, in infants less than 35 weeks GA, similar guidelines are not available, despite observational evidence that suggest preterm infants less than 35 weeks GA are more susceptible to BIND at lower TB levels than more mature infants. Lack of an evidence-based consensus on the management of hyperbilirubinemia in the preterm infant is due to the variability of clinical manifestations and spectrum of BIND, lack of reliable and predictive measures of bilirubin neurotoxicity, and the uncertainty of the relative risks and benefits of interventions to reduce TB levels (ie, phototherapy and exchange transfusions), particularly in the extremely low birth weight (ELBW) infant (birth weight [BW] ≤1000 g).

Hyperbilirubinemia in the premature infant <35 weeks GA will be reviewed here. The diagnosis, evaluation, and management of hyperbilirubinemia in the late preterm and term infant are discussed separately. (See "Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants" and "Evaluation of unconjugated hyperbilirubinemia in term and late preterm infants" and "Treatment of unconjugated hyperbilirubinemia in term and late preterm infants".)

EPIDEMIOLOGY

The prevalence of kernicterus in premature infants is uncertain. A retrospective study reported a 4 percent rate of kernicterus based upon characteristic postmortem neuropathological findings (ie, bilirubin staining and neuronal necrosis) in 81 preterm infants (gestational age [GA] <34 weeks) who died after 48 hours of life [2].

                    

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jul 2014. | This topic last updated: Mar 3, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004; 114:297.
  2. Watchko JF, Claassen D. Kernicterus in premature infants: current prevalence and relationship to NICHD Phototherapy Study exchange criteria. Pediatrics 1994; 93:996.
  3. Watchko JF, Maisels MJ. Jaundice in low birthweight infants: pathobiology and outcome. Arch Dis Child Fetal Neonatal Ed 2003; 88:F455.
  4. Okumura A, Kidokoro H, Shoji H, et al. Kernicterus in preterm infants. Pediatrics 2009; 123:e1052.
  5. Bhutani VK, Johnson LH, Shapiro SM. Kernicterus in sick and preterm infants (1999-2002): a need for an effective preventive approach. Semin Perinatol 2004; 28:319.
  6. Turkel SB, Guttenberg ME, Moynes DR, Hodgman JE. Lack of identifiable risk factors for kernicterus. Pediatrics 1980; 66:502.
  7. Kim MH, Yoon JJ, Sher J, Brown AK. Lack of predictive indices in kernicterus: a comparison of clinical and pathologic factors in infants with or without kernicterus. Pediatrics 1980; 66:852.
  8. Amin SB. Clinical assessment of bilirubin-induced neurotoxicity in premature infants. Semin Perinatol 2004; 28:340.
  9. Ahlfors CE, Amin SB, Parker AE. Unbound bilirubin predicts abnormal automated auditory brainstem response in a diverse newborn population. J Perinatol 2009; 29:305.
  10. Amin SB, Charafeddine L, Guillet R. Transient bilirubin encephalopathy and apnea of prematurity in 28 to 32 weeks gestational age infants. J Perinatol 2005; 25:386.
  11. Oh W, Tyson JE, Fanaroff AA, et al. Association between peak serum bilirubin and neurodevelopmental outcomes in extremely low birth weight infants. Pediatrics 2003; 112:773.
  12. Hulzebos CV, van Dommelen P, Verkerk PH, et al. Evaluation of treatment thresholds for unconjugated hyperbilirubinemia in preterm infants: effects on serum bilirubin and on hearing loss? PLoS One 2013; 8:e62858.
  13. Yeo KL, Perlman M, Hao Y, Mullaney P. Outcomes of extremely premature infants related to their peak serum bilirubin concentrations and exposure to phototherapy. Pediatrics 1998; 102:1426.
  14. Graziani LJ, Mitchell DG, Kornhauser M, et al. Neurodevelopment of preterm infants: neonatal neurosonographic and serum bilirubin studies. Pediatrics 1992; 89:229.
  15. van de Bor M, Ens-Dokkum M, Schreuder AM, et al. Hyperbilirubinemia in low birth weight infants and outcome at 5 years of age. Pediatrics 1992; 89:359.
  16. O'Shea TM, Dillard RG, Klinepeter KL, Goldstein DJ. Serum bilirubin levels, intracranial hemorrhage, and the risk of developmental problems in very low birth weight neonates. Pediatrics 1992; 90:888.
  17. Nagar G, Vandermeer B, Campbell S, Kumar M. Reliability of transcutaneous bilirubin devices in preterm infants: a systematic review. Pediatrics 2013; 132:871.
  18. Wennberg RP, Ahlfors CE, Bhutani VK, et al. Toward understanding kernicterus: a challenge to improve the management of jaundiced newborns. Pediatrics 2006; 117:474.
  19. Nakamura H, Yonetani M, Uetani Y, et al. Determination of serum unbound bilirubin for prediction of kernicterus in low birthweight infants. Acta Paediatr Jpn 1992; 34:642.
  20. Hulzebos CV, van Imhoff DE, Bos AF, et al. Usefulness of the bilirubin/albumin ratio for predicting bilirubin-induced neurotoxicity in premature infants. Arch Dis Child Fetal Neonatal Ed 2008; 93:F384.
  21. Oh W, Stevenson DK, Tyson JE, et al. Influence of clinical status on the association between plasma total and unbound bilirubin and death or adverse neurodevelopmental outcomes in extremely low birth weight infants. Acta Paediatr 2010; 99:673.
  22. Ahlfors CE. Criteria for exchange transfusion in jaundiced newborns. Pediatrics 1994; 93:488.
  23. Lipsitz PJ, Gartner LM, Bryla DA. Neonatal and infant mortality in relation to phototherapy. Pediatrics 1985; 75:422.
  24. Morris BH, Oh W, Tyson JE, et al. Aggressive vs. conservative phototherapy for infants with extremely low birth weight. N Engl J Med 2008; 359:1885.
  25. Hintz SR, Stevenson DK, Yao Q, et al. Is phototherapy exposure associated with better or worse outcomes in 501- to 1000-g-birth-weight infants? Acta Paediatr 2011; 100:960.
  26. Tyson JE, Pedroza C, Langer J, et al. Does aggressive phototherapy increase mortality while decreasing profound impairment among the smallest and sickest newborns? J Perinatol 2012; 32:677.
  27. Okwundu CI, Okoromah CA, Shah PS. Prophylactic phototherapy for preventing jaundice in preterm or low birth weight infants. Cochrane Database Syst Rev 2012; 1:CD007966.
  28. Morris BH, Tyson JE, Stevenson DK, et al. Efficacy of phototherapy devices and outcomes among extremely low birth weight infants: multi-center observational study. J Perinatol 2013; 33:126.
  29. Lee KS, Gartner LM. Management of unconjugated hyperbilirubinemia in the newborn. Semin Liver Dis 1983; 3:52.
  30. Brown AK, Kim MH, Wu PY, Bryla DA. Efficacy of phototherapy in prevention and management of neonatal hyperbilirubinemia. Pediatrics 1985; 75:393.
  31. Maisels MJ. Neonatology: Pathophysiology and Management of the Newborn, 6th ed, Avery GB, Fletcher MA, Macdonald MG (Eds), Lippincott Williams & Wilkins, 2005.
  32. Ives NK. Neonatal jaundice. In: Textbook of Neonatology, 3rd ed, Rennie JM (Ed), Churchill Livingston, Edinburgh 2005. p.675.
  33. Maisels MJ, Watchko JF. Treatment of jaundice in low birthweight infants. Arch Dis Child Fetal Neonatal Ed 2003; 88:F459.
  34. Cashore WJ. Bilirubin and jaundice in the micropremie. Clin Perinatol 2000; 27:171.
  35. Maisels MJ, Watchko JF, Bhutani VK, Stevenson DK. An approach to the management of hyperbilirubinemia in the preterm infant less than 35 weeks of gestation. J Perinatol 2012; 32:660.
  36. Bratlid D, Nakstad B, Hansen TW. National guidelines for treatment of jaundice in the newborn. Acta Paediatr 2011; 100:499.